ChemicalBook >> CAS DataBase List >>GNE-3511

GNE-3511

CAS No.
1496581-76-0
Chemical Name:
GNE-3511
Synonyms
CS-2506;GNE-3511;GNE-3511 ,E2378;GNE3511;GNE 3511;GNE35Chemicalbook11;DLK Inhibitor, GNE-3511;GNE-3511, 10 mM in DMSO;2-((6-(3,3-DIFLUOROPYRROLIDIN-1-YL)-4-(1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE;2-{[6-(3,3-DIFLUOROPYRROLIDIN-1-YL)-4-[1-(OXETAN-3-YL)PIPERIDIN-4-YL]PYRIDIN-2-YL]AMINO}PYRIDINE-4-CARBONITRILE;2-[[6-(3,3-difluoropyrrolidin-1-yl)-4-[1-(oxetan-3-yl)piperidin-4-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile
CBNumber:
CB93146612
Molecular Formula:
C23H26F2N6O
Molecular Weight:
440.49
MDL Number:
MFCD28502215
MOL File:
1496581-76-0.mol
MSDS File:
SDS
TDS File:
TDS
Last updated:2026-08-20 20:20:01
Product description Number Pack Size Price
DLK Inhibitor, GNE-3511 5.33168 10 mg $269
GNE-3511 ≥98% 19174 1mg $48
GNE-3511 ≥98% 19174 5mg $160
GNE-3511 ≥98% 19174 10mg $230
GNE-3511 ≥98% 19174 25mg $514
More product size

GNE-3511 Properties

Boiling point 579.0±50.0 °C(Predicted)
Density 1.37±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO:25.63(Max Conc. mg/mL);58.18(Max Conc. mM)
Methanol:1.0(Max Conc. mg/mL);2.27(Max Conc. mM)
form A crystalline solid
pka 7.23±0.40(Predicted)
color Light yellow to yellow
InChIKey RHFIAUKMKYHHFA-UHFFFAOYSA-N
SMILES C1(NC2=NC(N3CCC(F)(F)C3)=CC(C3CCN(C4COC4)CC3)=C2)=NC=CC(C#N)=C1
UNSPSC Code 12352200
NACRES NA.77

SAFETY

Risk and Safety Statements

Symbol(GHS)  Exclamation Mark (GHS07)
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501
WGK Germany  WGK 3
HS Code  2934999090
Storage Class 11 - Combustible Solids
NFPA 704
0
2 0

GNE-3511 price More Price(47)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 5.33168 DLK Inhibitor, GNE-3511 1496581-76-0 10 mg $269 2026-04-30 Buy
Cayman Chemical 19174 GNE-3511 ≥98% 1496581-76-0 1mg $48 2026-04-30 Buy
Cayman Chemical 19174 GNE-3511 ≥98% 1496581-76-0 5mg $160 2026-04-30 Buy
Cayman Chemical 19174 GNE-3511 ≥98% 1496581-76-0 10mg $230 2026-04-30 Buy
Cayman Chemical 19174 GNE-3511 ≥98% 1496581-76-0 25mg $514 2026-04-30 Buy
Product number Packaging Price Buy
5.33168 10 mg $269 Buy
19174 1mg $48 Buy
19174 5mg $160 Buy
19174 10mg $230 Buy
19174 25mg $514 Buy

GNE-3511 Chemical Properties,Uses,Production

Description

GNE-3511 is a selective and highly potent inhibitor of dual leucine zipper kinase (DLK). It also inhibits phosphorylated JNKand is highly selective for DLK over other MAP kinases. In an MPTP mouse model of Parkinson’s disease, a high dose of GNE-3511 completely suppresses phosphorylated c-Jun (p-c-Jun) expression, while a low dose moderately reduces its expression. Study has also shown that GNE03511 displayed concentration-dependent protection of neurons from degeneration in vitro and demonstrated dose-dependent activity in two different animal models of disease. These results suggest that GNE-3511 may have therapeutic potential in multiple indications.

References

Patel, S, et al. "Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models. " Journal of Medicinal Chemistry 58.1(2015):401-18.
https://www.caymanchem.com/product/19174

Uses

GNE-3511 is a potent and selective dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. GNE-3511 displays concentration-dependent protection of neurons from degeneration in vitro and demonstrated dose-dependent activity in two different animal models of disease. GNE-3511 displays protection of primary neurons in an in vitro axon degeneration assay as well as activity in the mouse models of glaucoma/optic neuropathy (optic nerve crush) and Parkinson’s disease (MPTP) after oral dosing.

Biological Activity

Cell permeable: yes', 'Primary Target
DLK', 'Reversible: yes

in vivo

GNE-3511 (oral gavage; 75 mg/kg; single) suppresses CYP-induced nociceptive behavior by inhibiting DLK in mice[2].
GNE-3511 (oral gavage; 75 mg/kg; single) suppresses CYP-induced edema and hemorrhage in mouse bladder[2].
GNE-3511 (iv.; 1 mg/kg or po.; 5 mg/kg) exhibits moderate in vivo plasma clearances, moderate volumes of distribution, short half-lives, and brain penetration[2].
Pharmacokinetic Parameters of GNE-3511 (iv.; 1 mg/kg or po.; 5 mg/kg)[2].

species CLp (mL/min/kgVdss (L/kgt1/2 (h)F (%)Bu/PuCSF/Pu
mouse562.50.6450.24 at 6 h
rat303.71.8630.70.4
dog416.54320.4
cynomolgous163.12.4190.6
Animal Model:Cystitis mouse model[1]
Dosage:75 mg/kg
Administration:oral gavage;75 mg/kg; single
Result:Significantly reduced the number of nociceptive behavior as well as nociceptive score.
Had no impact on bladder weight, did not induce bladder edema or hemorrhage and significantly suppressed CYP-induced increase in bladder weight, bladder edema, and hemorrhage.
Animal Model:mouse, rat, cynomolgus and dog[2]
Dosage:1 mg/k, 5 mg/kg
Administration:iv.; 1 mg/kg or po.; 5 mg/kg
Result:Exhibited moderate in vivo plasma clearances, moderate volumes of distribution, short half-lives and brain penetration.

GNE-3511 Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 93)Suppliers
Supplier Tel Email Country ProdList Advantage
TargetMol Chemicals Inc.
+1-781-999-5354; +1-00000000000 marketing@targetmol.com United States 32431 58
BOC Sciences
16314854226; +8616314854226 inquiry@bocsci.com United States 19852 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 sales@sarms4muscle.com China 10378 58
TargetMol Chemicals Inc.
+1-781-999-5354; support@targetmol.com United States 38999 58
Zibo Hangyu Biotechnology Development Co., Ltd
+86-0533-2185556 +86-15965530500 nickzhang@hangyubiotech.com China 9930 58
HANGZHOU LEAP CHEM CO., LTD.
+86-571-87711850 +86-15355479329 market18@leapchem.com China 43303 58
Aladdin Scientific
tp@aladdinsci.com United States 50108 58
Amadis Chemical Company Limited
571-89925085 sales@amadischem.com China 131885 58
ShangHai Caerulum Pharma Discovery Co., Ltd. 18149758185 18149758185 sales-cpd@caerulumpharma.com China 3493 58
Bide Pharmatech Ltd. 400-164-7117 18317119277 product02@bidepharm.com China 40000 60

View Lastest Price from GNE-3511 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
GNE-3511 pictures 2026-08-20 GNE-3511
1496581-76-0
$43.00-118.00 99.51% 10g TargetMol Chemicals Inc.
  • GNE-3511 pictures
  • GNE-3511
    1496581-76-0
  • $43.00-118.00
  • 99.51%
  • TargetMol Chemicals Inc.

GNE-3511 Spectrum

2-[[6-(3,3-difluoropyrrolidin-1-yl)-4-[1-(oxetan-3-yl)piperidin-4-yl]pyridin-2-yl]amino]pyridine-4-carbonitrile 2-{[6-(3,3-DIFLUOROPYRROLIDIN-1-YL)-4-[1-(OXETAN-3-YL)PIPERIDIN-4-YL]PYRIDIN-2-YL]AMINO}PYRIDINE-4-CARBONITRILE CS-2506 GNE3511;GNE 3511 GNE-3511 2-((6-(3,3-DIFLUOROPYRROLIDIN-1-YL)-4-(1-(OXETAN-3-YL)PIPERIDIN-4-YL)PYRIDIN-2-YL)AMINO)ISONICOTINONITRILE 4-Pyridinecarbonitrile, 2-[[6-(3,3-difluoro-1-pyrrolidinyl)-4-[1-(3-oxetanyl)-4-piperidinyl]-2-pyridinyl]amino]- GNE35Chemicalbook11 Inhibitor,MAP kinase kinase kinase, MEKK, MAPKKK,inhibit,neurodegenerative diseases,brain-penetrant,GNE 3511,MAP3K,GNE-3511,dual leucine zipper kinase (DLK),oral GNE-3511, 10 mM in DMSO DLK Inhibitor, GNE-3511 GNE-3511 ,E2378 1496581-76-0 C23H26F2N6O API